Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Tax Provisions (2016 - 2025)

Amicus Therapeutics filings provide 10 years of Tax Provisions readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 121.35% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.3 million, a 0.18% change, with the full-year FY2025 number at $27.3 million, changed 0.18% from a year prior.
  • Tax Provisions hit $1.5 million in Q4 2025 for Amicus Therapeutics, down from $17.0 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $17.0 million in Q3 2025 to a low of -$14.2 million in Q4 2022.
  • Median Tax Provisions over the past 5 years was $2.8 million (2021), compared with a mean of $3.0 million.
  • The widest YoY moves for Tax Provisions: up 2310.44% in 2022, down 576.82% in 2022.
  • Amicus Therapeutics' Tax Provisions stood at $3.0 million in 2021, then crashed by 576.82% to -$14.2 million in 2022, then skyrocketed by 115.36% to $2.2 million in 2023, then crashed by 411.73% to -$6.8 million in 2024, then soared by 121.35% to $1.5 million in 2025.
  • The last three reported values for Tax Provisions were $1.5 million (Q4 2025), $17.0 million (Q3 2025), and $5.2 million (Q2 2025) per Business Quant data.